Aida Pharmaceuticals, Inc. said it is developing a potential cancer drug that seeks to trigger cell death in certain types of cancer. Vasostatin-Apo2L, a pre-clinical product being developed by Aida's Shanghai Qiaer subsidiary, is a recombinant fusion protein that integrates the function of extracted fragments of Vasostatin, an inhibitor of angiogenesis and tumor growth, with the function of Rh-Apo2L, which induces the apoptosis of cancer cells. It has shown positive results in the lab.
Aida's researchers believe that the integration of Vasostatin-Apo2L will have higher efficacy in certain cancer treatments than currently prescribed methods. Aida estimates that Vasostatin will have a target market of 80,000-100,000 patients per year after it is successfully brought to market and this will contribute significantly to Aida's revenue.
Vasostatin-Apo2L is developed by the same research team that created Rh-Apo2L. Rh-Apo2L has successfully completed its phase II clinical testing and is going to file application with the PRC government's State Food and Drug Administration to start the phase III trials. The development of Vasostatin-Apo2L will benefit strongly from the experience garnered in the research, manufacturing and distribution of Rh-Apo2L.
Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China.